Key result
Primary aldosteronism was characterized by a reduction in urinary extracellular vesicle expression of AQP1 and AQP2 compared with essential hypertension, with a combined 6-protein panel yielding an AUC of 0.86 for disease discrimination.
Why the study?
Urinary extracellular vesicles can provide non-invasive pathophysiological information, prompting evaluation of whether their proteomic profile can aid in the differential characterization of essential hypertension and primary aldosteronism.
Can proteomic analysis of urinary extracellular vesicles differentiate between essential hypertension and primary aldosteronism?
Population
Patients with essential hypertension (EH= 12) and primary aldosteronism (PA=24)
Comparison
Essential hypertension vs primary aldosteronism subtypes (BPA vs APA)
Authors
Loading...
uEVs proteomic signatures may distinguish primary aldosteronism from essential hypertension; leaves open clinical utility pending prospective validation.
Observational (n=36)
Yes
Can proteomic analysis of urinary extracellular vesicles differentiate between essential hypertension and primary aldosteronism?
Effect estimate: AUC 0.86
Urinary extracellular vesicle proteomics, specifically reduced AQP1 and AQP2 expression, may serve as a non-invasive biomarker to differentiate primary aldosteronism from essential hypertension.
Bertolone et al. (2023) conducted an observational in Primary Aldosteronism and Essential Hypertension (n=36). Primary aldosteronism vs. Essential hypertension was evaluated on Discrimination of primary aldosteronism from essential hypertension using urinary extracellular vesicle proteins (AUC 0.86). Primary aldosteronism was characterized by a reduction in urinary extracellular vesicle expression of AQP1 and AQP2 compared with essential hypertension, with a combined 6-protein panel yielding an AUC of 0.86 for disease discrimination.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: